These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 2109379)

  • 41. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
    Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
    J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery.
    Baiocchi G; Scambia G; Benedetti P; Menichella G; Testa U; Pierelli L; Martucci R; Foddai ML; Bizzi B; Mancuso S
    Cancer Res; 1993 Mar; 53(6):1297-303. PubMed ID: 7680283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis.
    Mizuhara H; Uno M; Seki N; Yamashita M; Yamaoka M; Ogawa T; Kaneda K; Fujii T; Senoh H; Fujiwara H
    Hepatology; 1996 Jun; 23(6):1608-15. PubMed ID: 8675184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients.
    Carreno M; Yang WC; Esquenazi V; Fuller L; Burke G; Milgrom M; Roth D; Ranjan D; Miller J
    Transplantation; 1990 Feb; 49(2):408-15. PubMed ID: 1689519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
    Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
    J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.
    Norman DJ; Vincenti F; de Mattos AM; Barry JM; Levitt DJ; Wedel NI; Maia M; Light SE
    Transplantation; 2000 Dec; 70(12):1707-12. PubMed ID: 11152101
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxicity of OKT3 increases with dosage: a controlled study in renal transplant recipients.
    Parlevliet KJ; Bemelman FJ; Yong SL; Hack CE; Surachno J; Wilmink JM; ten Berge IJ; Schellekens PT
    Transpl Int; 1995; 8(2):141-6. PubMed ID: 7766296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model.
    Choi I; Schmitt WE; Bähre A; Little M; Cochlovius B
    Immunol Lett; 2002 Feb; 80(2):125-8. PubMed ID: 11750044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
    Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome.
    Eason JD; Pascual M; Wee S; Farrell M; Phelan J; Boskovic S; Blosch C; Mohler KM; Cosimi AB
    Transplantation; 1996 Jan; 61(2):224-8. PubMed ID: 8600628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.
    Jaffers GJ; Fuller TC; Cosimi AB; Russell PS; Winn HJ; Colvin RB
    Transplantation; 1986 May; 41(5):572-8. PubMed ID: 3085297
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome.
    Alegre ML; Gastaldello K; Abramowicz D; Kinnaert P; Vereerstraeten P; De Pauw L; Vandenabeele P; Moser M; Leo O; Goldman M
    Transplantation; 1991 Oct; 52(4):674-9. PubMed ID: 1833865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. OKT3 monoclonal antibody induces production of colony-stimulating factor(s) for granulocytes and macrophages in cultures of human T lymphocytes and adherent cells.
    Platzer E; Rubin BY; Lu L; Welte K; Broxmeyer HE; Moore MA
    J Immunol; 1985 Jan; 134(1):265-71. PubMed ID: 3917276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunologic monitoring during OKT3 therapy.
    Chatenoud L
    Clin Transplant; 1993 Aug; 7(4 Pt 2):422-30. PubMed ID: 10146352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
    Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y
    Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts.
    Sissolak G; Hoffbrand AV; Mehta AB; Ganeshaguru K
    Leukemia; 1992 Nov; 6(11):1155-60. PubMed ID: 1434798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hemopoietin-1 activity of interleukin-1 (IL-1) on acute myeloid leukemia colony-forming cells (AML-CFU) in vitro: IL-1 induces production of tumor necrosis factor-alpha which synergizes with IL-3 or granulocyte-macrophage colony-stimulating factor.
    Delwel R; van Buitenen C; Salem M; Oosterom R; Touw I; Löwenberg B
    Leukemia; 1990 Aug; 4(8):557-60. PubMed ID: 2201834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.